Alessandra Tedeschi MD, Department of Hematology, Azienda Ospedaliera Niguarda Ca' Granda in Milan, Italy, discusses the long-term findings of the phase III RESONATE-2 trial during the 2019 European Hematology Association Congress.

Ibrutinib, a once-daily BTK inhibitor, is approved for the frontline treatment of patients with chronic lymphocytic leukemia (CLL). The RESONATE-2 study, a phase III open-label trial, compared the efficacy and safety of the agent in the first-line setting versus chlorambucil in older patients, aged 65 years or older, with CLL.

The study demonstrated that ibrutinib, used as a single agent, had sustained benefit in terms of overall survival (OS) and progression-free survival (PFS), even for patients who had high-risk genomic features. Responses to the agent improved over time. With 66 months of follow-up, more than half of the 269 patients enrolled remain on treatment.

According to Tedeschi, treating older patients with CLL has always been a challenge, because many patients are unfit, and they may have comorbidities or intolerance to immunotherapy. Ibrutinib has provided a useful, more easily tolerated treatment option that has performed well in this patient population in terms of PFS and OS.

2019 European Hematology Association Congress

Alessandra Tedeschi MD

Articles

Dr. Tedeschi on Frontline Ibrutinib for Older Patients With CLL